#ESC26: Arrowhead claims safety edge over Ionis as triglyceride battle draws closer

MUNICH — Arrowhead is on course to crash Ionis Pharmaceuticals’ party. Arrowhead’s RNA interference drug Redemplo looked safer as well as effective in two late-stage trials in patients with high levels of dangerous fatty molecules called ...